
    slow accrual of patients.
  
['nasopharyngeal carcinoma']
['cisplatin']

        Inclusion Criteria:

          -  -Pathologically confirmed NPC

          -  Completed a definitive course of intensity-modulated photon radiation therapy (IMXT)
             to a total dose of ≥ 66 Gy

          -  Recurrence diagnosed more than 12 months after the initial course of IMXT

          -  Age ≥ 18 and < 70 years of age

          -  Karnofsky Performance Score ≥70

          -  Willing to accept adequate contraception for women with childbearing potential

          -  Ability to understand character and individual consequences of the clinical trial

          -  Willing to sign the written informed consent; Informed consent must be signed before
             the enrollment in the trial

        Exclusion Criteria:

          -  Local recurrence of NPC diagnosed within 12 months from the completion of previous
             course of radiation therapy

          -  Presence of distant metastasis

          -  Technology used other than IMXT (including brachytherapy following IMXT) for the
             treatment of initial diagnosis of NPC

          -  Pregnant or lactating women

          -  Patients who have not yet recovered from acute toxicities of prior therapies

          -  A diagnosis of malignancy other than CIS of the cervix, BCC and SCC of the skin within
             the past 5 years

          -  Refusal of the patient to participate into the study
      